Equities

Profile data is unavailable for this security.

About the company

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme. It partners with Alnylam Pharmaceuticals.

  • Revenue in USD (TTM)44.25bn
  • Net income in USD13.07bn
  • Incorporated1994
  • Employees100.41k
  • Location
    Sanofi SA54 rue la BoetiePARIS 75008FranceFRA
  • Phone+33 153774000
  • Fax+33 153774463
  • Websitehttps://www.sanofi.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
SAN:PAR since
announced
Transaction
value
Synthorx IncAnnounced09 Dec 201909 Dec 2019Announced4.16%2.45bn
Data delayed at least 15 minutes, as of Aug 12 2020 08:22 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Vertex Pharmaceuticals Incorporated5.40bn2.08bn68.21bn3.00k33.109.0631.2012.627.917.9120.5928.910.62643.678.601,800,895.0024.135.4829.326.9987.7187.5038.519.033.60--0.06490.0036.5948.30119.39--8.06--
Zoetis Inc6.34bn1.62bn74.56bn10.60k46.4225.0036.3211.763.383.3813.266.280.52711.286.41598,113.2013.4411.6215.2713.7169.9566.8325.4918.902.6010.070.720422.907.475.528.4620.8020.6417.02
Gilead Sciences, Inc.22.17bn-257.00m85.38bn11.80k--4.7476.993.85-0.2426-0.242617.5114.380.37224.916.731,879,153.00-0.481818.07-0.577621.8878.5783.42-1.2939.312.23-18.130.570525.341.46-2.04-1.34-14.958.17--
Sanofi SA (ADR)44.25bn13.07bn129.47bn100.41k9.781.718.762.935.195.1517.6229.640.3331.405.22440,664.809.443.6911.364.3967.8168.3728.3410.781.3835.080.2821--5.483.30-32.69-7.414.56--
Amgen, Inc.24.30bn7.30bn137.43bn23.40k19.1712.9113.305.6612.2412.2440.7618.180.39071.515.301,038,504.0011.7410.8314.1412.6778.2381.7530.0434.011.8110.320.762541.54-1.623.09-6.588.74-9.2318.91
Bristol-Myers Squibb Co34.86bn-563.00m142.29bn30.00k--2.9023.664.08-0.1033-0.103317.2721.780.38055.686.221,162,067.00-0.58948.56-0.720311.2169.9472.59-1.5517.511.368.690.48772.4515.8910.49-30.8911.419.712.64
Eli Lilly And Co22.95bn5.62bn144.07bn33.63k24.5135.2021.056.286.156.1525.104.280.56921.514.41682,521.9013.938.7619.8812.2878.6776.6224.4816.770.939922.640.792664.423.842.6239.4514.17-2.875.65
AbbVie Inc36.23bn6.91bn163.55bn47.00k20.3911.1216.144.514.554.5523.288.340.35063.255.241,207,567.006.739.908.4312.7273.3177.1419.2021.340.69786.350.855879.291.5710.7636.5534.62-2.0420.86
Data as of Aug 11 2020. Currency figures normalised to Sanofi SA's reporting currency: US Dollar USD

Institutional shareholders

4.56%Per cent of shares held by top holders
HolderShares% Held
Dodge & Coxas of 31 Mar 202048.26m1.92%
Fisher Asset Management LLCas of 30 Jun 202018.16m0.72%
Fidelity Management & Research Co. LLCas of 31 Mar 202014.22m0.57%
BlackRock Investment Management LLCas of 31 Mar 20207.98m0.32%
Invesco Advisers, Inc.as of 31 Mar 20206.96m0.28%
Managed Account Advisors LLCas of 31 Mar 20205.34m0.21%
Morgan Stanley & Co. International Plcas of 31 Mar 20203.81m0.15%
Hotchkis & Wiley Capital Management LLCas of 31 Mar 20203.35m0.13%
Lazard Asset Management LLCas of 31 Mar 20203.30m0.13%
Macquarie Investment Management Business Trustas of 31 Mar 20203.10m0.12%
More ▼
Data from 31 Mar 2020 - 30 Jun 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.